Why Every M&A Deal Needs an Independent Company Diagnostic

Every M&A process starts with the seller's story. The information memorandum is a polished document designed to present the company in the best possible light. The financial projections curve upward. The competitive positioning looks strong. The risks are acknowledged briefly and then explained away. None of this is dishonest, necessarily. It is simply the nature of a document prepared by someone who is trying to sell something.

The Information Asymmetry Problem

The fundamental challenge in any acquisition is information asymmetry. The seller knows the company intimately. The buyer is trying to develop an accurate picture from limited data, managed access to management, and a set of documents curated by the seller's advisors.

Traditional due diligence addresses this asymmetry through financial audits, legal reviews, and operational assessments. These are necessary but not sufficient. Financial audits verify that the numbers are accurate. They do not assess whether the business model is sustainable. Legal reviews identify existing liabilities. They do not evaluate whether the competitive landscape is shifting in ways that will create future liabilities. Operational assessments check that the business runs today. They do not evaluate whether it will run the same way under new ownership.

Independent company diagnostics fill the gaps between these traditional due diligence streams. They provide a structured, data-driven assessment of the company's health across dimensions that the seller's materials may understate or omit entirely.

What the Information Memorandum Does Not Mention

Seller materials are optimized for narrative coherence. They present a story where everything fits together: strong market position, growing revenue, capable management, and clear path to further growth. The things that do not fit the story tend to get minimized or excluded.

Customer concentration is a common omission. The information memorandum might describe a "diversified customer base" while the actual data shows that three customers account for 55% of revenue. The IM will highlight the total number of customers (which might be impressive) rather than the revenue distribution (which might be concerning).

Revenue quality is another area where seller materials tell an incomplete story. The IM reports total revenue growth but may not distinguish between organic growth and growth from one-time projects, price increases that have not yet triggered customer pushback, or channel partnerships that carry lower margins. An independent diagnostic that decomposes revenue by type, source, and sustainability paints a very different picture than the aggregate growth rate.

Competitive dynamics often get presented statically in the IM. The seller describes their current competitive position as if it will persist indefinitely. An independent assessment that tracks competitive trends, win rate changes, and market share movements might reveal that the company's position is eroding, even if current financial results do not yet reflect it.

Employee and organizational health is perhaps the most underrepresented area in seller materials. The IM might mention management tenure and key hires but will not disclose that three critical engineers are interviewing elsewhere, that the sales team has turned over 60% in the past year, or that a toxic middle management layer is driving departure of high performers. These organizational issues directly impact the achievability of the deal thesis.

The Case for Automated Assessment

Traditional independent assessments (hiring a consulting firm to conduct a commercial due diligence review) are thorough but expensive and time-consuming. A typical commercial due diligence engagement costs $200,000 to $500,000 and takes four to six weeks. This is appropriate for large transactions but can be disproportionate for deals in the $10 million to $100 million range, which is exactly where independent assessment is arguably most valuable because smaller companies tend to have more concentrated risks.

Automated company diagnostic platforms can produce a comprehensive assessment at a fraction of the cost and time. They cannot replace the qualitative judgment calls that experienced deal professionals make, but they can provide the analytical foundation that those judgment calls should be based on.

The most useful automated assessments cover financial health scoring (including trend analysis and benchmark comparisons), competitive positioning analysis (using available market data and public information), risk identification and scoring (customer concentration, key person dependency, market risk), and operational efficiency benchmarking. This baseline analysis gives the buyer a structured, independent view of the company that can be compared against the seller's narrative.

Timing and Integration Into the Deal Process

The most value from an independent diagnostic comes when it is conducted early in the process, before the buyer has committed significant resources and emotional investment to the deal. An assessment run during the initial screening phase can identify red flags that save weeks of wasted due diligence effort and prevent the buyer from developing cognitive biases that come from spending months working on a deal.

At the letter-of-intent stage, a more detailed assessment can inform valuation discussions and help structure deal terms that address identified risks. If customer concentration is flagged as a material risk, the buyer can propose retention guarantees or valuation adjustments tied to customer retention outcomes.

During formal due diligence, the independent assessment serves as a checklist and comparison framework. Findings from the diagnostic can guide where the due diligence team focuses its limited time. If the diagnostic flags declining competitive position as a concern, the team can prioritize customer interviews and competitive analysis rather than spending equal time on every area.

The Cost of Not Having Independent Data

Buyers who rely solely on seller-provided information and their own internal analysis expose themselves to a specific type of risk: they can only verify or challenge what they know to ask about. The information memorandum frames the conversation, and everything the buyer does in due diligence is, to some degree, a response to that framing.

An independent diagnostic reframes the conversation. It generates its own set of questions based on what the data reveals rather than what the seller chose to emphasize. This reframing is where the diagnostic pays for itself many times over, by identifying the questions the buyer would not have thought to ask based on the seller's materials alone.

In an environment where deal multiples remain elevated and competition for quality assets is intense, the discipline of seeking an independent view of every target company is not just good practice. It is a competitive advantage for buyers who want to make informed decisions rather than optimistic ones.

Related Reading

• Beyond Mega-Cap AI: Finding Tomorrow's Winners by Analyzing Non-Tech Companies Adopting AI
• Building an Investment Thesis With Only Public Data
• Company Analysis for Journalists and Investigative Reporters
• Detecting Market Mispricing in AI Adopters: How Fintech Tools Can Spot First-Mover Valuation Gaps
• Due Diligence in 90 Minutes Instead of 90 Days